Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

The company recently wowed investors with clinical trial results.

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

Hospitals and health systems are rapidly adopting AI-powered tools, connected medical devices, advanced analytics and emerging biotechnology solutions. Most organizations evaluate these technologies ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...